In 2024, Jiangzhong Pharmaceutical Co., Ltd. officially announced the change of its stock abbreviation from ‘Jiangzhong Pharmaceutical’ to ‘China Resources Jiangzhong,’ while retaining its original stock code (600750). This renaming signifies a deeper integration with its controlling shareholder, China Resources Pharmaceutical Group, and underscores its strategic role as the core traditional Chinese medicine (TCM) platform within the China Resources Group. Originally a well-known TCM company based in Jiangxi Province, Jiangzhong Pharmaceutical gained widespread recognition for products such as ‘Jianwei Xiaoshi Tablets’ (digestive aid) and ‘Compound Herba Sarcandrae Lozenges.’ Since being acquired by China Resources Pharmaceutical in 2019, the company has continuously enhanced its brand, distribution channels, R&D capabilities, and management systems. The name change not only reinforces the strong backing of the China Resources state-owned enterprise brand but also boosts market recognition and investor confidence, supporting high-quality growth in its TCM business. Moving forward, China Resources Jiangzhong will focus on therapeutic areas such as gastrointestinal health, respiratory care, and tonics, accelerate innovation in TCM development, expand its presence in the broader health industry, and strive to become a globally influential leader in modern traditional Chinese medicine.
2024年，江中药业股份有限公司正式宣布将其证券简称由“江中药业”变更为“华润江中”，证券代码保持不变（600750）。此次更名标志着公司与控股股东华润医药集团的整合进一步深化，也体现了其作为华润集团旗下中医药板块核心企业的战略定位。江中药业原为江西本土知名中药企业，以“健胃消食片”“复方草珊瑚含片”等产品广为人知。自2019年被华润医药控股后，公司在品牌、渠道、研发及管理等方面持续优化升级。此次更名不仅强化了“华润”这一央企品牌背书，也有助于提升市场认知度和投资者信心，推动中医药业务高质量发展。未来，华润江中将继续聚焦消化、呼吸、补益等优势治疗领域，加快创新中药研发，拓展大健康产业布局，致力于打造具有国际影响力的现代中药领军企业。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22140.html